Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

183.98 -0.55 (-0.30%)
Streaming Delayed Price Updated: 9:40 AM EDT, Aug 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Analyst Scoreboard: 5 Ratings For Glaukos ↗
 
Via Benzinga
News headline image
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds ↗
Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds. 
Via Benzinga
News headline image
How Is The Market Feeling About Glaukos? ↗
 
Via Benzinga
News headline image
A Closer Look at 7 Analyst Recommendations For Glaukos ↗
 
Via Benzinga
News headline image
Navigating 11 Analyst Ratings For Glaukos ↗
 
Via Benzinga
News headline image
Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings) ↗
 
Via Benzinga
News headline image
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
10 Analysts Have This To Say About Glaukos ↗
 
Via Benzinga
News headline image
Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings) ↗
 
Via Benzinga
News headline image
Analyst Ratings For Glaukos ↗
 
Via Benzinga
News headline image
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024 ↗
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
7 Leading MedTech Stocks for Next-Gen Health Solutions ↗
With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar. 
Via InvestorPlace
News headline image
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst ↗
Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%. 
Via Benzinga
Topics Earnings
News headline image
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
5 Analysts Have This To Say About Glaukos ↗
 
Via Benzinga
News headline image
Glaukos: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024 ↗
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Earnings Scheduled For February 21, 2024 ↗
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
News headline image
Analyst Ratings For Glaukos ↗
 
Via Benzinga
News headline image
Unveiling 7 Analyst Insights On Glaukos ↗
 
Via Benzinga
News headline image
Analyst Ratings for Glaukos ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About Glaukos ↗
 
Via Benzinga
News headline image
Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst ↗
Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S. 
Via Benzinga
News headline image
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst ↗
Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog... 
Via Benzinga
News headline image
Dow Extends Rally As Treasury Yields Tank ↗
The Dow Jones Industrial Average is charging full speed ahead, up 78 points this afternoon after yesterday closing at record highs, on the heels of the Federal Reserve's rate decision. 
Via Talk Markets
Topics Economy Stocks
News headline image
FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients ↗
The FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.